To play this presentation please log in.
Don't have an account?
Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.
Faculty
Claire Harrison
Professor
Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
Professor of Myeloproliferative Neoplasms
John Mascarenhas
MD
Icahn School of Medicine at Mount Sinai, New York, New York
Director, Adult Leukemia Program, Professor of Medicine, The Tisch Cancer Institute
TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of myelofibrosis.
LEARNING OBJECTIVES
- Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with myelofibrosis (MF) regarding their long-term prognosis.
- Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with primary and secondary MF.
- Appraise available research findings informing the safety and efficacy of approved JAK inhibitors for patients with MF, including those with thrombocytopenia and anemia.
- Assess available research findings with combination regimens incorporating JAK inhibitors and other novel therapies, and consider the potential clinical application of these approaches.
- Increase participation in active research protocols by counseling appropriately selected patients regarding the biological rationale for and available efficacy and safety data with novel investigational agents and strategies for MF.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology and hematology.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YiR2024/MF/Presentation/CME.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Professor Claire Harrison
Professor of Myeloproliferative Neoplasms
Guy’s and St Thomas’ NHS Foundation Trust
London, United Kingdom
Advisory Committees: Galecto Inc, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Keros Therapeutics, Novartis, Silence Therapeutics, Sobi; Consulting Agreements: Galecto Inc, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Keros Therapeutics, Novartis, Silence Therapeutics, Sobi, Takeda Pharmaceutical Company Limited; Contracted Research: Galecto Inc, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Novartis, Silence Therapeutics, Sobi; Data and Safety Monitoring Boards/Committees: Galecto Inc, Incyte Corporation, Novartis, Silence Therapeutics; Speakers Bureaus: AOP Health, GSK, Incyte Corporation, Novartis.
John Mascarenhas, MD
Director, Adult Leukemia Program
Professor of Medicine
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York
Consulting Agreements: Bristol Myers Squibb, Disc Medicine, Geron Corporation, GSK, Incyte Corporation, Italfarmaco SpA, Kartos Therapeutics, Karyopharm Therapeutics, Keros Therapeutics, Merck, MorphoSys, Novartis, PharmaEssentia, Roche Laboratories Inc, Sobi, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Disc Medicine, Incyte Corporation, Italfarmaco SpA, Kartos Therapeutics, Karyopharm Therapeutics, Novartis, PharmaEssentia, Sobi; Data and Safety Monitoring Boards/Committees: Incyte Corporation.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
These activities are supported by educational grants from Geron Corporation and Incyte Corporation.
Release date: May 2025
Expiration date: May 2026
After completing the post-test, learners may download and review the answers here in order to identify further areas of study.
Breccia M et al. Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI). Cancer 2025;131(7):e35801. Abstract
Duan M et al. The efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated myelofibrosis patients: The interim analysis of a prospective, open-label, multicenter, parallel-cohort, phase 2 study. ASH 2024;Abstract 1002.
Gagelmann N et al. Consistency of spleen and symptom reduction regardless of cytopenia in patients with myelofibrosis treated with pacritinib. Clin Lymphoma Myeloma Leuk 2024;24(11):796-803. Abstract
Gupta V et al. Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial. ASCO 2024;Abstract 6571.
Gupta V et al. Momelotinib vs ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. Leuk Lymphoma 2024;65(7):965-77. Abstract
Gupta V et al. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: Primary analysis of FREEDOM trial. Leuk Lymphoma 2024;65(9):1314-24. Abstract
Harrison C et al. Hematological improvement and other clinical benefits of elritercept as monotherapy and in combination with ruxolitinib in participants with myelofibrosis from the ongoing phase 2 Restore trial. ASH 2024;Abstract 997.
Harrison CN et al. Longitudinal assessment of transfusion intensity in patients with JAK inhibitor-naive or -experienced myelofibrosis treated with momelotinib. Clin Lymphoma Myeloma Leuk 2025;25(3):199-211. Abstract
Harrison CN et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): Results from a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol 2024;11(10):e729-40. Abstract
Harrison CN et al. Momelotinib versus continued ruxolitinib or best available therapy in JAK inhibitor-experienced patients with myelofibrosis and anemia: Subgroup analysis of SIMPLIFY-2. Adv Ther 2024;41(9):3722-35. Abstract
Koschmieder S et al. Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: Recommendations from a global consensus group. Leukemia 2024;38(8):1831-8. Abstract
Masarova L et al. A phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib. ASH 2024;Abstract 999.
Mascarenhas J et al. Selinexor plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis: SENTRY phase 3 study design. Future Oncol 2025;21(7):807-13. Abstract
Mascarenhas JO et al. Disease-modifying activity of navtemadlin correlates with clinical responses in a randomized, multicenter, global phase 3 study (BOREAS) in JAK-inhibitor relapsed/refractory myelofibrosis. ASH 2024;Abstract 483.
Mascarenhas JO et al. Imetelstat versus best available therapy in patients with intermediate-2 or high-risk myelofibrosis relapsed or refractory to Janus kinase inhibitor in IMpactMF, a randomized, open-label, phase 3 trial. ASH 2024;Abstract 1808.1.
Mascarenhas JO et al. Results from the randomized, multicenter, global phase 3 BOREAS study: Navtemadlin versus best available therapy in JAK inhibitor relapsed/refractory myelofibrosis. ASH 2024;Abstract 1000.
Mascarenhas JO et al. Trial update from IMproveMF, an ongoing, open-label, dose-escalation and -expansion, phase 1/1B trial to evaluate the safety, pharmacokinetics, and clinical activity of the novel combination of imetelstat with ruxolitinib in patients with intermediate-1, intermediate-2, or high-risk myelofibrosis (MF). ASH 2024;Abstract 998.
Mascarenhas JO et al. Updated results from the phase 3 Manifest-2 study of pelabresib in combination with ruxolitinib for Janus kinase inhibitor–naïve patients with myelofibrosis. ASH 2024;Abstract 3178.
Palandri F et al. Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study. Cancer 2024;130(24):4257-66. Abstract
Vachhani P et al. Clinical outcomes in patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications. ASH 2024;Abstract 4546.
Vachhani P et al. POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis who have a suboptimal response to ruxolitinib. ASH 2024;Abstract 1808.2.
Watts JM et al. Safety and efficacy of bromodomain and extra-terminal inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis and other advanced myeloid neoplasms: A phase 1 study. ASH 2024;Abstract 658.